Risk factors for bone loss with prostate cancer in korean men not receiving androgen deprivation therapy

International Braz J Urol

Volumn 35, Issue 2, 2009, Pages 183-189

  Kim, Sun Ouck ^a   Kang, Taek Won ^a   Kwon, Dongdeuk ^a   Park, Kwangsung ^a   Ryu, Soo Bang ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Androgen deprivation therapy; Osteoporosis; Prostate neoplasm; Prostate specific antigen

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ARTICLE; BLOOD; BODY MASS; BONE DENSITY; ETHNOLOGY; HUMAN; KOREA; MALE; MIDDLE AGED; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROSTATE TUMOR; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BODY MASS INDEX; BONE DENSITY; HUMANS; KOREA; LINEAR MODELS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TESTOSTERONE;

EID: 76249113244     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382009000200008     Document Type: Article

References (19)

1. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343: 604-10.
2. Daniell HW: Osteoporosis after orchiectomy for pros tate cancer. J Urol. 1997; 157: 439-44.
3. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K: Incidence of bone fracture in patients receiving lutein-izing hormone-releasing hormone agonists for prostate cancer. BJU Int. 2000; 86: 449-52.
4. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, et al.: Skeletal fracture associated with androgen suppression induced osteoporosis: the clini cal incidence and risk factors for patients with prostate cancer. J Urol. 2001; 166: 1724-8.
5. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM: Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002; 87: 3656-61.
6. Blake GM, Fogelman I: Principles of bone densitometry. In: Bilezikian JP, Raisz LG, and Rodan GA (ed.), Principles of Bone Biology. San Diego, Academic Press. 1996; pp. 1313-32.
7. McGrath SA, Diamond T: Osteoporosis as a compli cation of orchiectomy in 2 elderly men with prostatic cancer. J Urol. 1995; 154: 535-6.
8. Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ: Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004; 64: 335-40.
9. Stetler-Stevenson WG, Aznavoorian S, Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993; 9: 541-73.
10. Ershler WB, Harman SM, Keller ET: Immunologic aspects of osteoporosis. Dev Comp Immunol. 1997; 21:487-99.
11. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al.: Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997; 89: 755-64.
12. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, et al.: Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 2001; 61: 5652-9.
13. Komori T: Runx2, a multifunctional transcription fac tor in skeletal development. J Cell Biochem. 2002; 87: 1-8.
14. Karsenty G: The genetic transformation of bone biology. Genes Dev. 1999; 13: 3037-51.
15. Yingling JM, Blanchard KL, Sawyer JS: Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004; 3: 1011-22.
16. Bonewald LF, Mundy GR: Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res. 1990; 250: 261-76.
17. Eriksson A, Carlström K: Prognostic value of serum hormone concentrations in prostatic cancer. Prostate. 1988; 13: 249-56.
18. Higano CS: Management of bone loss in men with prostate cancer. J Urol. 2003; 170: S59-63; discussion S64.
19. Conde FA, Aronson WJ: Risk factors for male osteo porosis. Urol Oncol. 2003; 21: 380-3.